http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012133318-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-9121 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 |
| filingDate | 2011-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012133318-A |
| titleOfInvention | IDENTIFICATION, EVALUATION AND TREATMENT OF CANCER DISEASES WITH GENETIC OR ACQUIRED RESISTANCE TO ALK INHIBITORS |
| abstract | 1. A method for identifying a subject suffering from a cancer or having a risk of developing a cancer, as having an increased risk of insensitivity to treatment with an ALK inhibitor, comprising: a. sampling a specified patient; and b. analyzing said sample for the presence of one or more mutant ALK polynucleotide molecules, or one or more mutant ALK polypeptides, or both, the presence of one or more mutant ALK polynucleotide molecules, or one or more mutant ALK polypeptides, or both that said subject has an increased risk of insensitivity to treatment with an ALK inhibitor. 2. The method of claim 1, wherein said subject has not previously been treated with an ALK inhibitor, or has previously been treated with an ALK inhibitor, and has developed at least partial resistance to an ALK inhibitor. The method of claim 1, wherein said cancer is selected from the group consisting of anaplastic large cell lymphoma, neuroblastoma, breast cancer, cancer of the rectum and colon, inflammatory myofibroblast tumors and non-small cell lung cancer. The method according to claim 1 or 3, wherein said ALK inhibitor is selected from the group consisting of PF-02341066, PDD, 2-methyl-11- (2-methylpropyl) -4-oxo-4,5,6,11,12 , 13-hexahydro-2H-indazole [5,4-a] pyrrole [3,4-c] carbazol-8-yl [4- (dimethylamino) benzyl] carbamate, (1S, 2S, 3R, 4R) -3- ({5-chloro-2 - [(1-ethyl-2,3,4,5-tetrahydro-6-methoxy-2-oxo-1H-1-benzazepin-7-yl) amino] -4-pyrimidinyl} amino ) bicyclo [2.2.1] hept-5-en-2-carboxamide and NVP-TAE684.5. The method according to claim 1, wherein said sample is selected from the group consisting of sputum, bronchoalveolar rinse, pleural effusion, tissue, whole blood |
| priorityDate | 2010-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 29.